


# Prevalence of skin mf and OV16+ versus number of MDA rounds (1 year post-MDA)

By measurement type (lines) and MDA coverage (columns) and pre-control CMFL (rows)

OV16 serology sensitivity 80% and specificity 99%, OV16 tested up to age 10, skin mf tested from age 5 onwards

Measurement type — Skin mf — OV16 hypothesis 1 - - OV16 hypothesis 2 ···· OV16 hypothesis 3




# Prevalence of skin mf and OV16+ by age one year after varying number of MDA rounds (lines)

By pre-control endemicity (columns) and measurement type (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 60%

Number of MDA rounds: 0 (dash-dot), 5 (dashed), 10 (dotted), 15 (dash-dot-dot), 20 (long-dashed), 25 (solid)




# Prevalence of skin mf and OV16+ by age one year after varying number of MDA rounds (lines)

By pre-control endemicity (columns) and measurement type (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 70%

Number of MDA rounds: 0 (dotted), 5 (dashed), 10 (dash-dot), 15 (dotted), 20 (dashed), 25 (solid)




# Prevalence of skin mf and OV16+ by age one year after varying number of MDA rounds (lines)

By pre-control endemicity (columns) and measurement type (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 80%


Number of MDA rounds: 0 (dotted), 5 (dash-dot), 10 (dashed), 15 (long-dashed), 20 (short-dashed), 25 (solid)



# Probability of elimination versus number of MDA rounds

By MDA coverage (lines) and pre-control CMFL (panels)

MDA coverage — 80% - - 70% ···· 60%




# Probability of elimination versus OV16+ prevalence (1 year post-MDA)

By MDA coverage (lines) and OV16 hypothesis (columns) pre-control CMFL (rows)

OV16 serology sensitivity 80% and specificity 99%, OV16 tested up to age 10

MDA coverage — 80% - - 70% ···· 60%




# Probability of elimination versus OV16+ prevalence (1 year post-MDA)

By pre-control CMFL (lines) and sample population (columns) and OV16 hypothesis (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 60%

Pre-control CMFL (mf/ss)  80  55  30  10  5




# Probability of elimination versus OV16+ prevalence (1 year post-MDA)

By pre-control CMFL (lines) and sample population (columns) and OV16 hypothesis (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 70%

Pre-control CMFL (mf/ss) --- 80 ··· 55 ····· 30 - - - 10 — 5





# Probability of elimination versus OV16+ prevalence (1 year post-MDA)

By pre-control CMFL (lines) and sample population (columns) and OV16 hypothesis (rows)

OV16 serology sensitivity 80% and specificity 99%, MDA coverage 80%

Pre-control CMFL (mf/ss) --- 80 ··· 55 ····· 30 - - - 10 — 5

